NCT02942355View on ClinicalTrials.gov

Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

December 7, 2016

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Female Breast CarcinomaBreast Cancer

Interventions

DRUG

anastrozole

Anastrozole by mouth daily

DRUG

Palbociclib

Palbociclib by mouth daily days 1-21 every 28 days

Trial Locations (1)

28204

Levine Cancer Institute, Charlotte

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

collaborator

Atrium Health Levine Cancer Institute

OTHER

lead

Wake Forest University Health Sciences

OTHER